Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -36,819 | -16,633 | N/A | N/A | -20,328 |
| Depreciation Amortization | 244 | 151 | N/A | N/A | 132 |
| Accounts receivable | N/A | -15,000 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | -885 | -3,591 | N/A | N/A | -221 |
| Other Working Capital | -13,195 | -27,715 | N/A | N/A | -5,859 |
| Other Operating Activity | 15,586 | 31,645 | 0 | 0 | 3,266 |
| Operating Cash Flow | $-35,069 | $-31,143 | $N/A | $N/A | $-23,010 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -191,551 | N/A | N/A | N/A | N/A |
| PPE Investments | -2,134 | -2,098 | N/A | N/A | -266 |
| Investing Cash Flow | $-193,685 | $-2,098 | $N/A | $N/A | $-266 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 301,505 | 301,505 | N/A | N/A | 23,276 |
| Financing Cash Flow | $301,505 | $301,505 | $N/A | $N/A | $23,276 |
| End Cash Position | 72,751 | 268,264 | N/A | N/A | N/A |
| Net Cash Flow | $72,751 | $268,264 | $N/A | $N/A | $0 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,069 | -31,143 | N/A | N/A | -23,010 |
| Capital Expenditure | -2,134 | -2,098 | N/A | N/A | -266 |
| Free Cash Flow | -37,203 | -33,241 | 0 | 0 | -23,276 |